109 Results

People

  1. Giralt
    Giralt
  2. Landau
    Landau
  3. Zelenetz
    Zelenetz
  4. Hassoun
    Hassoun
  5. Landgren
    Landgren
  6. Lesokhin
    Lesokhin
  7. Chiosis
    Chiosis
  8. Horwitz
    Horwitz
  9. Korde
    Korde
  10. Mailankody
    Mailankody

Groups

  1. Center for Hematologic Malignancies (109)
  2. Department of Medicine (101)
  3. Hematologic Malignancies, Division of (99)
  4. Bone Marrow Transplant (46)
  5. Lymphoma (36)
  6. Survivorship Research (29)
  7. Hematologic Malignancies Research (28)
  8. Myeloma (27)
  9. Epidemiology and Biostatistics (15)
  10. GSK Faculty (14)
  1. "bortezomib"
  2. "Center for Hematologic Malignancies"
Formats
  1. Journal Article (94)
  2. Review (7)
  3. Research Letter (4)
  4. Correspondence (2)
  5. Book Section (1)
  6. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (109)
  2. Department of Medicine (101)
  3. Hematologic Malignancies, Division of (99)
  4. Bone Marrow Transplant (46)
  5. Lymphoma (36)
  6. Survivorship Research (29)

More Groups

People
  1. Sergio Giralt (28)
  2. Heather Landau (20)
  3. Andrew Zelenetz (14)
  4. Carl Landgren (13)
  5. Hani Hassoun (13)
  6. Alexander Lesokhin (10)

More People

Years
  1. 2024 (1)
  2. 2023 (9)
  3. 2022 (7)
  4. 2021 (4)
  5. 2020 (8)
  6. 2019 (3)

More Years

Publications
  1. Blood (6)
  2. Leukemia and Lymphoma (6)
  3. Biology of Blood and Marrow Transplantation (4)
  4. Blood Cancer Journal (4)
  5. British Journal of Haematology (4)
  6. Cancer (4)

More Publications

Publishers
  1. Elsevier Inc. (15)
  2. Nature Publishing Group (13)
  3. American Society of Hematology (10)
  4. Taylor & Francis Group (8)
  5. American Society of Clinical Oncology (6)
  6. John Wiley & Sons (5)

More Publishers

Results (109)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
    Journal Article

    Delforge, M.; Patel, K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T. S.; Arnulf, B.; Cavo, M.; Nooka, A.; more...
    The Lancet Haematology (2024)

    Fulltext@MSK | Save
  • Cross fire: Daratumumab-based therapies are standard of care in newly diagnosed multiple myeloma
    Review

    Korde, N.; Usmani, S. Z.
    Hematology/ Oncology and Stem Cell Therapy (2023)

    Fulltext@MSK | Save
  • Few and far between: Clinical management of rare extranodal subtypes of mature T-cell and NK-cell lymphomas
    Review

    Stuver, R.; Epstein-Peterson, Z. D.; Horwitz, S. M.
    Haematologica (2023)

    Fulltext@MSK | Save
  • Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
    Journal Article

    Coffey, D. G.; Maura, F.; Gonzalez-Kozlova, E.; Diaz-Mejia, J. J.; Luo, P.; Zhang, Y.; Xu, Y.; Warren, E. H.; Dawson, T.; Lee, B.; more...
    Nature Communications (2023)

    Fulltext@MSK | Save
  • Increased CXCL10 is seen at 1-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy
    Research Letter

    Mohan, M.; Janz, S.; Brazauskas, R.; Dwinell, M. B.; Teng, B. Q.; Yun, G.; Dong, J.; Pasquini, M. C.; Giralt, S.; Landau, H.; more...
    Bone Marrow Transplantation (2023)

    Fulltext@MSK | Save
  • Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Journal Article

    Tan, C. R.; Derkach, A.; Nemirovsky, D.; Ciardiello, A.; Diamond, B.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Maclachlan, K.; more...
    Blood Cancer Journal (2023)

    Fulltext@MSK | Save
  • Report of consensus panel 7 from the 11th International Workshop on Waldenström Macroglobulinemia on priorities for novel clinical trials
    Conference Paper

    Tam, C. S.; Kapoor, P.; Castillo, J. J.; Buske, C.; Ansell, S. M.; Branagan, A. R.; Kimby, E.; Li, Y.; Palomba, M. L.; Qiu, L.; more...
    W.B. Saunders Co-Elsevier Inc. (2023)

    Fulltext@MSK | Save
  • Bridging radiation rapidly and effectively cytoreduces high-risk relapsed/refractory aggressive B cell lymphomas prior to chimeric antigen receptor T cell therapy
    Journal Article

    Hubbeling, H.; Silverman, E. A.; Michaud, L.; Tomas, A. A.; Shouval, R.; Flynn, J.; Devlin, S.; Wijetunga, N. A.; Tringale, K. R.; Batlevi, C.; more...
    Transplantation and Cellular Therapy (2023)

    Fulltext@MSK | Save
  • Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy
    Journal Article

    Van Oekelen, O.; Nath, K.; Mouhieddine, T. H.; Farzana, T.; Aleman, A.; Melnekoff, D. T.; Ghodke-Puranik, Y.; Shah, G. L.; Lesokhin, A.; Giralt, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Extreme body mass index and survival in newly diagnosed multiple myeloma patients
    Correspondence

    Shah, U. A.; Whiting, K.; Devlin, S.; Ershler, R.; Kanapuru, B.; Lee, D. J.; Tahri, S.; Gwise, T.; Rustad, E. H.; Mailankody, S.; more...
    Blood Cancer Journal (2023)

    Fulltext@MSK | Save